Foresee Pharmaceuticals has shown that a long-acting version of its injectable prostate cancer med Camcevi can help patients ...
In one of the largest analyses conducted so far on ovarian stimulation strategies, researchers have reported that the gonadotropin-releasing hormone (GnRH) antagonist protocol results in significantly ...
New evidence shows GnRH antagonist stimulation outperforms PPOS for oocyte yield in young high-risk IVF patients, supporting ...
Biohacker Bryan Johnson is typically known for his ongoing experiment to reverse his biological age and for spending a ...
FP-001 42 mg is an investigational, sustained-release formulation of a GnRH agonist being developed for the treatment of CPP. It is designed to provide continuous suppression of gonadotropin secretion ...
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute uri ...
Kissei Pharmaceutical Co ( ($JP:4547) ) has issued an announcement. Kissei Pharmaceutical has obtained Japanese manufacturing and marketing ...
Long-term pituitary down-regulation before in vitro fertilisation (IVF) for women with endometriosis
We reviewed the efficacy and safety of treating women with known endometriosis (a disease characterised by the presence of endometrial tissue outside the cavity of the womb) with ...
This valuable study investigates the oscillatory activity of gonadotropin-releasing hormone (GnRH) neurones in mice using GCaMP fiber photometry. It demonstrates three distinct patterns of oscillatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback